{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T13:48:39Z","timestamp":1762004919915,"version":"3.37.3"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T00:00:00Z","timestamp":1498694400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007819","name":"Allergan","doi-asserted-by":"publisher","award":["TEF-IT-41"],"award-info":[{"award-number":["TEF-IT-41"]}],"id":[{"id":"10.13039\/100007819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["UL1 TR001120"],"award-info":[{"award-number":["UL1 TR001120"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000049","name":"National Institute on Aging","doi-asserted-by":"publisher","award":["1P30AG044271-01A1"],"award-info":[{"award-number":["1P30AG044271-01A1"]}],"id":[{"id":"10.13039\/100000049","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1007\/s40265-017-0785-2","type":"journal-article","created":{"date-parts":[[2017,6,29]],"date-time":"2017-06-29T10:31:39Z","timestamp":1498732299000},"page":"1345-1351","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Early Use of Ceftaroline Fosamil in the United States Veterans Health Care System"],"prefix":"10.1007","volume":"77","author":[{"given":"Rachel S.","family":"Britt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kirk E.","family":"Evoy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly R.","family":"Reveles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly M.","family":"Sorensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary","family":"Bollinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christopher R.","family":"Frei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,6,29]]},"reference":[{"key":"785_CR1","unstructured":"Antibiotic resistance threats in the United States, 2013. Atlanta: United States Centers for Disease Control and Prevention (CDC); 2013. \n                    http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013\/pdf\/ar-threats-2013-508.pdf\n                    \n                  . Last accessed 26 Sept 2016."},{"key":"785_CR2","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1086\/655827","volume":"51","author":"GR Corey","year":"2010","unstructured":"Corey GR, Wilcox M, Talbot GH, Friedland HD, Baculik T, Witherell GW, Critchley I, Das AF, Thye D. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51:641\u201350.","journal-title":"Clin Infect Dis"},{"key":"785_CR3","doi-asserted-by":"crossref","unstructured":"Rank DR, Friedland HD, Laudano JB. Integrated safety summary of FOCUS 1 and FOCUS 2 trials: phase III randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii53\u20139.","DOI":"10.1093\/jac\/dkr099"},{"key":"785_CR4","unstructured":"Teflaro Package Insert, US Food and Drug Adminstration. 2016. \n                    http:\/\/www.allergan.com\/assets\/pdf\/teflaro_pi\n                    \n                  . Last accessed 26 Sept 2016."},{"key":"785_CR5","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1093\/jac\/dks006","volume":"67","author":"TT Ho","year":"2012","unstructured":"Ho TT, Cadena J, Childs LM, Gonzalez-Velez M, Lewis JS 2nd. Methicillin-resistant Staphylococcus aureus bacteraemia and endocarditis treated with ceftaroline salvage therapy. J Antimicrob Chemother. 2012;67:1267\u201370.","journal-title":"J Antimicrob Chemother"},{"key":"785_CR6","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","volume":"19","author":"JC Lin","year":"2013","unstructured":"Lin JC, Aung G, Thomas A, Jahng M, Johns S, Fierer J. The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients. J Infect Chemother. 2013;19:42\u20139.","journal-title":"J Infect Chemother"},{"key":"785_CR7","doi-asserted-by":"publisher","first-page":"2541","DOI":"10.1128\/AAC.02371-13","volume":"58","author":"AM Casapao","year":"2014","unstructured":"Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ. Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy. Antimicrob Agents Chemother. 2014;58:2541\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"785_CR8","doi-asserted-by":"publisher","unstructured":"Zasowski EJ, Trinh TD, Claeys KC, Casapao AM, Sabagha N, Lagnf AM, Klinker KP, Davis SL, Rybak MJ. Multicenter observational ftudy of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2017;61:e02015\u201316. doi:\n                    10.1128\/AAC.02015-16","DOI":"10.1128\/AAC.02015-16"},{"key":"785_CR9","doi-asserted-by":"publisher","first-page":"128","DOI":"10.3810\/pgm.2014.09.2807","volume":"126","author":"JD Evans","year":"2014","unstructured":"Evans JD, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of acute bacterial skin and skin structure infections in obese patients. Postgrad Med. 2014;126:128\u201334.","journal-title":"Postgrad Med"},{"key":"785_CR10","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1586\/17512433.2015.986461","volume":"8","author":"C Maggiore","year":"2015","unstructured":"Maggiore C, Pasquale T, Cole P, Friedland HD. Ceftaroline fosamil for treating skin and skin structure infections or community-acquired pneumonia in patients with renal insufficiency. Expert Rev Clin Pharmacol. 2015;8:141\u201353.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"42","key":"785_CR11","first-page":"109","volume":"2014","author":"G Udeani","year":"1995","unstructured":"Udeani G, Evans J, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of community-acquired bacterial pneumonia in elderly patients. Hosp Pract. 1995;2014(42):109\u201315.","journal-title":"Hosp Pract"},{"issue":"43","key":"785_CR12","first-page":"144","volume":"2015","author":"KS Kaye","year":"1995","unstructured":"Kaye KS, Udeani G, Cole P, Friedland HD. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia. Hosp Pract. 1995;2015(43):144\u20139.","journal-title":"Hosp Pract"},{"key":"785_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1097\/IPC.0000000000000191","volume":"23","author":"JA Vazquez","year":"2015","unstructured":"Vazquez JA, Maggiore CR, Cole P, Smith A, Jandourek A, Friedland HD. Ceftaroline fosamil for the treatment of Staphylococcus aureus bacteremia secondary to acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. Infect Dis Clin Pract (Baltim Md). 2015;23:39\u201343.","journal-title":"Infect Dis Clin Pract (Baltim Md)"},{"key":"785_CR14","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1093\/jac\/dkw062","volume":"71","author":"KJ Furtek","year":"2016","unstructured":"Furtek KJ, Kubiak DW, Barra M, Varughese CA, Ashbaugh CD, Koo S. High incidence of neutropenia in patients with prolonged ceftaroline exposure. J Antimicrob Chemother. 2016;71:2010\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"785_CR15","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/AAC.01471-15","volume":"60","author":"KW LaVie","year":"2015","unstructured":"LaVie KW, Anderson SW, O\u2019Neal HR Jr, Rice TW, Saavedra TC, O\u2019Neal CS. Neutropenia associated with long-term ceftaroline use. Antimicrob Agents Chemother. 2015;60:264\u20139.","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-017-0785-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0785-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-017-0785-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,16]],"date-time":"2020-05-16T22:36:09Z","timestamp":1589668569000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-017-0785-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,29]]},"references-count":15,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["785"],"URL":"https:\/\/doi.org\/10.1007\/s40265-017-0785-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"type":"print","value":"0012-6667"},{"type":"electronic","value":"1179-1950"}],"subject":[],"published":{"date-parts":[[2017,6,29]]},"assertion":[{"value":"29 June 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was supported by Allergan Pharmaceuticals (formerly Forest Pharmaceuticals) [TEF-IT-41 to CRF\u2019s institution].","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"CRF has received research grants, to his institution, for investigator-initiated cancer and infectious diseases research, from Allergan (formerly Forest), Bristol Myers Squibb, and Pharmacyclics in the past three years. RSB, KEE, GCL, KRR, KMS, XJ, and MB do not have any conflicts of interest to declare.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}